Fasciolosis medical therapy

Revision as of 15:28, 7 August 2015 by Turky Alkathery (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Fasciolosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fasciolosis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Endoscopy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fasciolosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fasciolosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fasciolosis medical therapy

CDC on Fasciolosis medical therapy

Fasciolosis medical therapy in the news

Blogs on Fasciolosis medical therapy

Directions to Hospitals Treating Fasciolosis

Risk calculators and risk factors for Fasciolosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical therapy

Anthelmintics

For high efficacy and safety, triclabendazole (Egaten®) in dose 10-12 mg/kg is drug of choice in human fasciolosis.[1] No drug alternatives are available for humans. On the other hand, nitazoxanide were successfully used in human fasciolosis treatment in Mexico.[2] Bithionol is another drug of choice used for treatment of fasciola hepatica.[3]

Antimicrobial Regimen

  • Preferred regimen: Triclabendazole 10 mg/kg PO one dose[4]
  • Note: Two-dose (double-dose) triclabendazole therapy can be given to patients who have severe or heavy Fasciola infections (many parasites) or who did not respond to single-dose therapy.
  • Alternative regimen: Nitazoxanide 500mg PO bid for 7 days

References

  1. Savioli, L., Chistulo, L., Montresor, A., 1999. New opportunities for the control of fascioliasis. Bull. WHO 77, 300.
  2. Rossignol, J.F., Abaza, H., Friedman, H., 1998. Successful treatment of human fascioliasis with nitazoxanide. Trans. Roy. Soc. Trop. Med. Hyg. 92, 103–104.
  3. Ramachandran, A., 2000. Pharmacology Recall.
  4. "Parasites - Fascioliasis".